Bombay High Court Warns Maharashtra FDA Over Cadila Pharmaceuticals' Aciloc Medicine Ban

• The Bombay High Court has warned the Maharashtra FDA against excessive enforcement powers.
• The regulator seized ₹2.45 crore worth of Cadila Pharmaceuticals' stock without a show-cause notice.
• Patients were left without access to essential medication for weeks, highlighting concerns about public health and patient rights.

Power has to be judiciously exercised. How to use the powers with adequate propriety is the question

The Bombay High Court has issued a stern warning to the Maharashtra FDA over its sudden ban on Cadila Pharmaceuticals' Aciloc medicine range, highlighting concerns about excessive enforcement powers and potential harm to patients. The court's intervention comes after the FDA halted sales and seized ₹2.45 crore worth of stock without issuing a show-cause notice, leaving patients without access to essential medication for weeks. This incident is not an isolated case; the regulator has been criticized previously for disproportionate enforcement action, with the court observing that it 'uses its powers like a sword to kill a mosquito.' The FDA's actions have disrupted Cadila's operations across the state, causing significant commercial losses and impacting patient care.

The Bombay High Court's decision is rooted in the principles of due process and proportionality. In its ruling, the court emphasized that regulatory authorities must exercise their powers with restraint and respect for individual rights. The FDA's failure to issue a show-cause notice before seizing stock has been deemed arbitrary and excessive, highlighting the need for regulators to balance enforcement with procedural fairness. This case underscores the importance of judicial oversight in ensuring that regulatory actions are lawful and proportionate.

The Bombay High Court's warning to the Maharashtra FDA has significant implications for patients who rely on essential medications like Aciloc. The regulator's actions have caused a 20-day disruption in patient access to these life-saving medicines, with potential long-term consequences for public health. The court's emphasis on protecting patient rights and interests underscores the need for regulators to prioritize proportionality and procedural fairness in their enforcement actions.

Lawyers should be aware of the Bombay High Court's warning to the Maharashtra FDA against using excessive enforcement powers, which may impact future regulatory actions and compliance with show-cause notices.

Source: Original reporting via The Hindu